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Abstract The brain demands oxygen and glucose to fulfill
its roles as the master regulator of body functions as diverse
as bladder control and creative thinking. Chemical and
electrical transmission in the nervous system is rapidly
disrupted in stroke as a result of hypoxia and hypoglyce-
mia. Despite being highly evolved in its architecture, the
human brain appears to utilize phylogenetically conserved
homeostatic strategies to combat hypoxia and ischemia.
Specifically, several converging lines of inquiry have
demonstrated that the transcription factor hypoxia-inducible
factor-1 (HIF1-1) mediates the activation of a large cassette
of genes involved in adaptation to hypoxia in surviving
neurons after stroke. Accordingly, pharmacological or
molecular approaches that engage hypoxic adaptation at
the point of one of its sensors (e.g., inhibition of HIF prolyl
4 hydroxylases) leads to profound sparing of brain tissue
and enhanced recovery of function. In this review, we
discuss the potential mechanisms that could subserve
protective and restorative effects of augmenting hypoxic
adaptation in the brain. The strategy appears to involve
HIF-dependent and HIF-independent pathways and more
than 70 genes and proteins activated transcriptionally and
post-transcriptionally that can act at cellular, local, and
system levels to compensate for oxygen insufficiency. The
breadth and depth of this homeostatic program offers a




Stroke is defined as injury to the brain accruing from a
vascular etiology. Strikingly, it has emerged as the third
leading cause of death and the leading cause of disability in
the USA. Accordingly, the estimated financial costs of
stroke are more than 50 billion dollars a year in the USA
alone. These financial costs do not begin to tell the story of
the personal suffering that amasses from the silent epidemic
of stroke disability—over 5 million Americans face the
challenges of handicaps from stroke each day. The
recognition of stroke as a leading age-associated public
health issue has led the government and the pharmaceutical
industry to expend enormous resources on developing
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e-mail: rratan@burke.orginterventions in the form of drugs that minimize brain
damage associated with stroke. Despite their promise, these
efforts have been disappointing and have left a nearly
indelible sense of frustration on the biomedical research
community [1]. In this chapter, we will discuss the
pathophysiology of stroke with particular attention to one
of its primary mediators, hypoxia, and attempt to revive a
sense of optimism and enthusiasm for stroke therapeutics
moving forward.
Ischemia is a process in which perfusion to tissue is
critically reduced creating a deficit in necessary brain fuels.
The brain is highly vulnerable to ischemia because the
eloquent functions it is assigned to carry out, in the
pluralistic society of organ functions, depend integrally on
energy—specifically adenosine triphosphate (ATP). The
brain comprises only 2% of body weight, but it utilizes
nearly 20% of cardiac output to achieve its supply of
essential nutrients including oxygen and glucose. Abnormal
central nervous system (CNS) symptoms begin to manifest
at 40–50% of normal resting hemispheric cerebral blood
flow resulting in slowing of the EEG, attenuation of evoked
potentials, and reduction in the membrane potential in
individual cortical neurons [2]. The resting membrane
potential must be maintained to allow proper neuronal
function, including synaptic activity and axonal conduction.
Once the neuronal membrane potential begins to dissipate,
neuronal function ceases. It is important to note that ATP
levels at this point may be normal or only slightly reduced
[3]. The reason for this inordinate sensitivity is not entirely
clear but is likely related to the Km of neurotransmitter
systems for ATP or their exquisite sensitivity to tissue
acidosis [4]. Gross deterioration and damage requires even
more severe reductions in blood flow to 20–30% of normal
resting hemispheric cerebral blood flow (Fig. 1). With this
level of ischemia, a deterioration of ionic membrane
gradients ensues, and the tissue begins to accumulate
hydrogen ions (acidosis) [5]. Changes in ionic fluxes likely
accrue directly from a reduction of intracellular ATP, a
failure of the Na
+/K
+ATPase activity, and increases in
intracellular Na
+ and extracellular K
+. The failure of ionic
homeostasis reflects loss of activity of multiple transporters
that normally maintain the electrochemical gradients nec-
essary for normal neuronal signal transduction [6, 7].
Among the ions deregulated, intracellular calcium appears
to play a critical role in further ion dyshomeostasis via the
calmodulin-dependent activation of neuronal nitric oxide
synthase (nNOS) [8–10]. Increased nNOS activity leads to
increase in the ambient levels of neuronal nitric oxide (NO)
[11]. Changes in NO coupled with ischemia-associated
increases in cytosolic and mitochondrially derived super-
oxide, combine to form toxic peroxynitrite. Peroxynitrite
can trigger cell death pathways via DNA damage, poly
Fig. 1 Neuronal hypoxia leads to calcium overload and production of
free radicals. Stroke is associated with a decrease in cerebral blood
flow to the brain. The consequent loss of metabolic fuels leads to
failure of sodium pumps leading to an intracellular accumulation of
sodium and calcium, depolarization, and activation of voltage
sensitive and ligand gated [N-methyl-D-aspartate (NMDA)] ion
channels. Increased in calcium in microdomains near the NMDA
receptor leads to activation of neuronal nitric oxide synthase. Global
dysregulation of calcium in the neuron leads to mitochondrial
overload and superoxide production. Nitric oxide and superoxide
combine to form peroxynitrite. Peroxynitrite can damage DNA
leading to PARP activation and consumption of NAD
+. It can also
activate TRPM2/7 channels leading to further calcium dysregulation.
Hypoxia is sensed by decreased activity of HIF prolyl 4 hydroxylases
that can lead to activation genetic responses capable of compensating
for the sentinel metabolic stress (decreased cerebral blood flow).
Decrease HIF PHD activity can also prevent death via HIF-
independent pathways. Acidosis and ROS can also combine with
HIF regulated prodeath proteins to trigger cell death
1332 J Mol Med (2007) 85:1331–1338(ADP-ribose)polymerase (PARP) activation, liberation of
apoptosis-inducing factor (AIF) from the mitochondria, and
activation of death signaling pathways leading to apoptosis
[12, 13]; alternatively, non-selective cation channels such as
TRPM2 and TRPM7 can be activated to ensure sustained
calcium overload and death [14]. Extracellular acidosis is
also postulated to activate acid sensing ion channels, which
also contribute to destruction of the normal ionic environ-
ment [15]. As one can appreciate from a partial description
of the sequence of events after stroke that occur in the
neuron alone, targeting a single molecule in the complex
parallel and serial pathways of acute hypoxia-ischemia will
not maintain neuronal survival (Fig. 2). It is also unlikely to
enhance the ability of energy-thirsty neurons to carry out
their sophisticated roles in maintaining posture, movement,
sequencing language, or making critical executive deci-
sions. Therefore, how might we move forward? One of the
most important advances in the treatment of complex
medical problems has been the discovery that multimodal
therapies can greatly enhance therapeutic efficiency. Treat-
ment of cancer, HIV infection, and tuberculosis with
multimodal therapies yields results that are not obtained
with the application of single therapeutic agents.
As stroke does not represent a single homogeneous
category of injury, it is also a poor candidate for a single
approach to treatment [16]. Challenges involved in promot-
ing recovery from stroke involve reducing the extent of
damage that occurs in acute injury. Moreover, many different
kinds of damage are found in individuals with stroke ranging
from necrotic, apoptotic, or parthanatotic death of neurons
[17, 18], demyelination of otherwise functional axons [19],
and transection of axons and subsequent loss of critical
neuronal populations [20]. Acute injury itself is extremely
complex, including waves of cell death, inflammatory
responses, edema, and scarring. Indeed, experimental studies
have continued to demonstrate that interventions that target
single aspects of the complex cascade, including blocking
ion gradients, scavenging free radicals, or enhancing growth
factors on their own are insufficient to overcome the
considerable barriers to protection against hypoxia and
ischemia in acute stroke [21].
Instructive data from the experimental paradigm of
ischemic preconditioning has pointed the way towards
novel strategies that can address the heterogeneity and
complexity inherent in stroke pathophysiology [22]. Ani-
mals subjected to a non-lethal exposure to hypoxia are
found to be more resistant to a host of subsequent lethal
stresses, including cerebral ischemia. The mechanism by
which a sublethal exposure to hypoxia can render the brain
resistant to cerebral ischemia and a host of other insults is a
topic of active investigation and debate. However, one
point appears irrefutable: The tolerance that develops after a
short duration of hypoxia involves not only the activation
or inactivation of pre-existing proteins but also de novo
gene expression [23, 24]. These transcriptional and post-
transcriptional mechanisms reflect a cassette of genes and
proteins that work collectively at the cellular, local, and
systemic levels to compensate for a discrepancy in oxygen
supply and demand. The findings suggest that under
conditions where adaptive homeostatic mechanisms are
appropriately engaged, damage to the brain can be
substantially lessened or even prevented (Fig. 3). Stroke
is, almost by definition, a failure of homeostasis. Accord-
ingly, identification of small molecules that augment
endogenous adaptive strategies provides a mechanism to
tilt the balance away from cell damage and death and
toward cell survival and repair (Fig. 3).
Examination of adaptive responses to hypoxia in the
central nervous system has affirmed that the family of
Fig. 2 Contribution of neurons and astrocytes in mediating excito-
toxic neuronal death. 1 Loss of ATP in ischemia leads to inhibition of
the Na
+/K
+ATPase and subsequent collapse of normal ionic gradients.
2 In turn, neuronal membrane depolarization activates voltage
sensitive Ca
2+ channels, which increase intracellular Ca
2+ and
stimulate vesicular glutamate release. Severe loss of ionic gradients
found in certain ischemic regions may also lead to the reversal of 3
neuronal specific and 4 astrocyte specific glutamate transporters,
which in the reverse mode act to release glutamate into the
extracellular space. 5 Cell swelling in cerebral ischemia, which is
mainly localized to astrocytes, likely activates swelling sensitive anion
channels, referred to as volume regulated anion channels (VRACs).
VRACs, which are permeable to organic osmolytes, contribute to
glutamate release predominantly in the ischemic penumbra. 6
Glutamate regulated NMDA receptors (NMDA-R) are activated by
(1) extracellular glutamate and (2) release of Mg
2+ from its pore after
membrane depolarization (in part due to activation of glutamate
regulated AMPA receptors, not shown). 7 NMDA-Rs are permeable to
Ca
2+ and as such, overabundant NMDA-R activation leads to an
intracellular Ca
2+ overload. This increase in intracellular Ca
2+ then
contributes to neuronal death via several mechanisms
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factors are central players [25–27]. HIF-1 was purified and
cloned as a result of a search for proteins that regulate the
expression of genes involved in hypoxic adaptation, such as
erythropoietin, vascular endothelial growth factor, and
glycolytic enzymes [27]. HIF is a heterodimeric transcrip-
tional activator composed of an inducible HIF-1α subunit
and a constitutively expressed HIF-1β subunit [28, 29].
HIF-1α stability is regulated via the activity of a class of
oxygen, 2-oxoglutarate, and iron dependent enzymes
known as the HIF prolyl-4 hydroxylases (HIF PHDs,
Fig. 4)[ 30]. As intracellular oxygen levels drop below a
critical threshold, these enzymes fail to hydroxylate HIF-
1α. As hydroxylation is required for the recruitment of the
constitutively active E3 Ubiquitin Ligase, Von Hippel
Lindau protein, HIF-1α becomes stabilized. HIF-1α can
partner with its constitutively expressed but induced partner
HIF-1β and translocate to the nucleus to regulate the
expression of a host of genes involved in hypoxic
adaptation [31]. Consistent with this model, several groups
have shown that HIF-1α immunoreactivity increases in
areas of the cortex that become hypoxic due to stroke [25,
32] An unanswered question has been whether HIF is also
upregulated in areas connected to but remote from the site
of ischemia. Indeed, neurons projecting to an area of
infarction are at risk for cell death due to a loss of trophic
support from their damaged targets. Moreover, neurons
projecting from an area of damage are at risk for cell death
due to a loss of trophic excitatory input from their targets.
An elegant recent study in non-human primates demon-
strated a dramatic increase in neuronal immunoreactivity
for HIF-1α and one of its target genes in the infarct and
peri-infarct region [33, 34]. Indeed, the neuronal immuno-
reactivity for HIF-1α increased from less than 5% to nearly
90% in both regions. Interestingly, areas remote to the area
of hypoxia and ischemia also experience increased HIF and
vascular endothelial growth factor (VEGF) levels but to a
quantitatively much smaller extent. Together, the published
rodent and primate histochemical studies support the
hypothesis that increased HIF protein levels resulting from
direct hypoxia and non-hypoxic mediators such as IGF-1
are a marker for surviving and regenerating neurons after
ischemia [32].
Pharmacological and molecular studies have provided
additional support for the notion that stabilization of HIF-1
after ischemia is associated with enhanced survival of
neurons. Small molecule hypoxia mimics, deferoxamine,
and cobalt chloride, were found to stabilize HIF-1α levels,
increase DNA binding to a cognate hypoxia response
element, and increase the expression of HIF target genes
in vitro cultured neurons (Zaman et al. [31]) and in vivo in
the intact brain (Fig. 4;[ 35]). Pretreatment or post-
treatment with desferrioxamine or cobalt chloride resulted
in reduced cell loss in models of focal or global ischemia in
vitro and in vivo [25, 31, 36–39]. Subsequent studies have
confirmed that hypoxia, iron chelation, or cobalt chloride
appear to confer protective effects on neurons via their
ability to inhibit HIF PHDs [35]. Emerging data indicate
Fig. 3 Drugs that augment endogenous homeostatic mechanisms will
more effectively neutralize the heterogeneity inherent in stroke
pathophysiology. As these pathways are already used by the body,
their activation can occur with decreased threat of toxicity. The term
“homeostasis” was coined by Walter Canon in the early twentieth
century. It refers to the innate tendency of organisms to mobilize
adaptive responses physiological and pathological perturbations that
ultimately return the system to a set point that is consistent with
survival. a The experimental paradigm of “ischemic preconditioning”
has shown that a short, sublethal exposure to hypoxia, or hypoxia-
ischemia induces homeostatic responses that make the organism
“immune” or “tolerant” to a lethal ischemic insult. Mechanistic
studies have revealed that tolerance is the consequence of activation
of pre-existing proteins and de novo gene expression. b According to
this model, stroke can be conceptualized as a failure of homeostasis.
Consequently, neurons die and the brain is permanently damaged.
c By extension, small molecules that engage homeostatic mechanisms
designed to alleviate hypoxia/ischemia early or enhance their
activation should tip the balance away from cell death and toward
survival and repair. Such small molecules are currently being
developed and represent a new generation of stroke therapies
1334 J Mol Med (2007) 85:1331–1338that inhibition of each of the three of the HIF PHD isoforms
(1–3) may lead to cell survival in the nervous system. Of
note, inhibition of each isoform may enhance survival via
distinct but mutually supportive pathways.
Our studies demonstrate that pharmacological inhibition of
PHDs, in vitro, leads to inhibition of oxidative stress-induced
death, an established mediator of neural injury and death in
stroke [35]. More recent studies indicate that molecular
suppression of HIF PHD 1 alone can mimic this effect
(Siddiq et al., unpublished observations). Interestingly, while
HIF-1, HIF-2, and cAMP response element-binding protein
are stabilized by PHD inhibition in neurons or astrocytes, the
molecular deletion or inhibition of each of these three
transcription factors fails to abrogate the protective effects
of PHD inhibition suggesting that other, as yet unidentified,
pathways are important in protection (Siddiq et al., unpub-
lished observations). Studies are underway to clarify whether
molecular deletion of PHD1 selectively in the CNS confers
resistance to stroke in a HIF-independent manner.
In contrast to PHD1, PHD2 appears to be the isoform
most important for tagging HIF for degradation. Deletion of
PHD2 but not PHD1 or PHD3 results in increased HIF and
VEGF protein and consequent angiogenesis in multiple
organs including the brain [40]. Underscoring PHD2’s
important role in HIF signaling, the expression level of
this isoform is significantly higher as compared to its
brethren [41]. Ischemia-induced PHD2 inhibition stabilizes
HIF and enhances expression of genes that mediate cellular
(e.g., glycolytic enzymes), local (vascular endothelial
growth factor), and systemic (erythropoietin, Epo) adaptive
responses to hypoxia or hypoxia-ischemia [42]. While Epo
is best known as a hematopoietic growth factor that can
enhance oxygen carrying capacity to tissue, it also has
organ-autonomous roles in the nervous system. Epo is
produced in astrocytes in response to hypoxia or ischemia
and mediates a number of responses critical to stroke
prevention and recovery [43, 44]. Epo can inhibit neuronal
death due to excitotoxicity or growth factor deprivation
[45–49]. It can also stimulate the proliferation of neural
progenitors in the germinal zones of the brain and enhance
Fig. 4 HIF prolyl 4 hydroxylases sense hypoxia and transduce a
critical insufficiency in oxygen in the brain into transcriptional and
post-transcriptional signal changes that mediate protection and repair.
Hypoxia regulates the activity of HIF PHDs via direct or indirect
mechanisms; production of peroxide via reduction in mitochondrial
ATP production and electron transport chain (ETC) impairment (1, 2);
accumulation of the tricarboxylic cycle (TCA) intermediates succinate
and fumarate (3); or direct inhibition of the activity of PHDs due to
lack of oxygen (4). Accumulation of hydrogen peroxide, succinate or
fumarate can inhibits the activity of PHDs by competing with 2-
oxoglutarate or by oxidizing the active site iron (5). Among its
numerous downstream effects, inhibition of HIF PHD activity leads to
stabilization of HIF-1α. Stabilized HIF-1α dimerizes with HIF-1β in
the nucleus and increases gene transcription (6)

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HIF-dependent increase in VEGF expression provides,
among other things, the appropriate angiogenic niche for
neuralprogenitorstosurvive[52]. New neurons could mediate
recovery responses via paracrine effects or due to direct par-
ticipation in functional circuits. A recent study affirmed the
requisite role for HIF transcription factors in mediating some
of the salutary effects of low molecular weight PHD
inhibitors given after cerebral ischemia [53]. Available
evidence suggests that these inhibitors are likely targeting
PHD2 to induce HIF and its gene targets in the CNS.
Inhibition of the third isoform of PHDs (PHD3) by
hypoxia or hypoxia mimetics has also been linked to
neuronal survival [54]. Freeman and colleagues first
identified PHD3 (then known as SM-20) as a message
and protein that is highly upregulated in sympathetic
neurons after growth factor deprivation. Subsequent studies
have shown that pharmacological or molecular deletion of
HIF PHD3 prevents apoptosis associated with trophic loss
in neurons and that the protection is HIF independent [55].
As target (post-synaptic) derived trophic factors appear to
be lost after stroke and result in cell death remote from the
infarct site, HIF PHD3 inhibition may be a rational strategy
for maintaining the viability of these neurons in evolving or
stable stroke.
From the above discussion, a model begins to emerge
whereby inhibition of HIF PHD1, 2, or 3 by hypoxia or
consequences of hypoxia can mediate HIF-dependent and
HIF-independent compensatory responses via distinct but
clearly reinforcing mechanisms. How does one reconcile
this model with observations from several laboratories,
including our own, that HIF PHD inhibition or HIF
activation leads to the upregulation of prodeath, Bcl-2
family proteins such as Puma, Bnip3, and NIX [56]?
Moreover, constitutive HIF activation has been associated
with potentiation and suppression of death [56]. These
findings appear to make perfect sense if one considers
apoptosis as an adaptive response to stress. After stroke,
oxygen may fall below a critical level rendering the prolyl
hydroxylases inactive. Accordingly, HIF is stabilized and it
translocates to the nucleus to upregulate genes involved in
preventing and executing death. The anthropomorphized
cell can be visualized stepping to the edge of a steep cliff in
response to a potentially lethal stress (Fig. 5). If adequate
compensation for hypoxia occurs, prodeath proteins are not
activated and the cell survives as a functional component of
a complex neural network—the cell moves away from the
cliff to survival promoting, terra firma. By contrast, if
oxidative stress, hypoxia, and acidosis dominate, indicating
that compensatory mechanisms have failed, then proapop-
Fig. 5 Adaptationtohypoxia-cellfateandbeyond.ExpressionofHIFin
neurons leads to the constitutive expression of proteins associated with
cell death(BNIP3,NIX,and PUMA)andcell survival(VEGF,glycolytic
enzymes, Epo, and p21 waf1/cip1). Similar prodeath gene expression is
found in neurons exposed to hypoxia or hypoxia mimetics despite the
absence of cell death. It appears the oxygen “starved” neurons have
stepped to the edge of the cliff. If during the ensuing hours to days the
neuron becomes acidotic or oxidized, then prodeath proteins such as
BNIP3 undergo a conformational change, insertion into the mitochon-
drial membrane, release of apoptotic effectors, and death. By contrast, if
the survivalgenes are effective in neutralizing the hypoxic stress(e.g.,no
acidosisoroxidativestress),thenthedeathgenesnevergetactivated.Our
studies indicate that antioxidants, short interfering RNAs to BNIP3 or
inhibitors of the HIF prolyl 4 hydroxylases tip the balance toward
survival (away from the cliff)
1336 J Mol Med (2007) 85:1331–1338totic proteins such as BNIP3 undergo a conformational
change, insertion into the mitochondrial membrane and
activation of permeabilization transition and release of
apoptotic effectors [57–59]. In the latter scenario, the cell
jumps off the cliff to preserve limiting resources for its
neighbors. The model suggests that state changes in the cell
(e.g., redox and pH) that follow the initial ischemic insult
will determine the fate of the tissue and potential for
recovery (Fig. 5). Of note, low molecular weight or peptide
inhibitors of the PHDs, antioxidants, and a small interfering
RNA to BNIP3 prevent the prodeath effects of HIF (Amino
et al., personal communication). These findings suggest that
engaging the adaptive response at an upstream point where
stress is detected by the cell (the stress sensor) is going to
be more effective in stemming cell loss and facilitating
repair than at the point of the transcription factor (HIF). It is
our hypothesis that engaging the adaptive response at an
upstream point in the pathway results in post-transcriptional
changes essential for the homeostatic response. These
changes in concert with transcriptional changes optimally
alleviate the discrepancy between oxygen supply and
demand.
The model has some clear predictions. First, low
molecular weight global inhibitors of the HIF prolyl 4
hydroxylases will be more effective at preventing injury
and repairing damage after stroke than selective isoform
inhibitors. These inhibitors will engage HIF-dependent and
HIF-independent pathways at cellular, local, and systemic
levels and ultimately alleviate the discrepancy in nutrient
supply and demand. They can also (via mechanisms that are
only beginning to be defined) divert HIF away from its
tendencies as a prodeath transcription factor. The ability of
single “drugs” to target an oligopoly of proteins (HIF
PHD1–3) to affect a concerted program of neuroprotection
involving more than 70 genes and larger number of proteins
suggests a strategy for overcoming the heterogeneity
inherent in stroke pathophysiology in the short term. While
a significant amount of work needs to be done to
adequately assess the viability of this strategy for human
therapeutics, the notion of augmenting endogenous adap-
tive programs via HIF PHDs to thwart disease continues to
gain currency.
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